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Disputes & Debates: Editors’ Choice
Steven Galetta, MD, FAAN, Section Editor
Reader response: The state of clinical research in neurology
Kimford J. Meador (Palo Alto, CA)
Neurology® 2018;91:983. doi:10.1212/WNL.0000000000006539
Hall et al.1 concluded that “The state of clinical research in neurology has remained relatively
stable over the last 10 years.” Sounds reassuring, but is it really? As noted, investigator-initiated
research could not be distinguished from clinical trial participation.1 Interactions with industry
are critical to establishing new therapies and diagnostic devices, but important clinical research
will never be addressed by industry. An increase in training opportunities for patient-oriented
researchers was seen, but their eﬀectiveness remains uncertain. Hall et al.1 stated that “fewer
neurology researchers are applying for NIH funding, with the greatest decrease found in the
number of early career award applicants.” The drop in early career applicants is particularly
concerning for the future of academic neurology.
In a 2016 American Academy of Neurology survey, academic neurologists spent an average
of 27.7% of their time on research and teaching combined (10% median time for each in-
dividually).2 This represents a marked decrease from themid 1980s, when the average combined
time was 58%.3 Thus, it is not surprising that the main barrier to conducting research listed by
Hall et al.1 was time (noted by 74% of clinical research responders). Thus, the state of clinical
research in academic neurology remains a concern.4,5
1. Hall DA, Ramos AR, Gelfand JM, et al. The state of clinical research in neurology. Neurology 2018;90:e1347–e1354.
2. Busis NA, Shanafelt TD, Keran CM, et al. Burnout, career satisfaction, and well-being among US neurologists in 2016. Neurology 2017;
88:797–808.
3. Schindler BA, Novack DH, Cohen DG, et al. The impact of the changing health care environment on the health and well-being of faculty
at four medical schools. Acad Med 2006;81:27–34.
4. Meador KJ. Decline of clinical research in academic medical centers. Neurology 2015;85:1171–1176.
5. Meador KJ. Reader response: the state of academic neurology departments in the United States, 2016: a national survey. Neurology
2018;90:487–488.
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Editors’ note: The state of clinical research in neurology
In their nationwide survey, Hall et al. reported that clinical research among American
neurologists over the last decade has remained relatively stable.While rates of NIH funding
remained steady during this period, Dr. Meador addresses an important concern that there
has been a fall in grant applications among early career neurologists, who represent the
future of academic neurology. In his commentary, Dr. Meador also acknowledges the
signiﬁcant reduction in the amount of time neurologists are permitted to dedicate to
research and teaching over the last several decades. Institutional and industry-sponsored
grants may augment the NIH research funding available for neurologists, but time remains
a major roadblock for budding clinician-scientists.
James E. Siegler III, MD, and Steven Galetta, MD
Neurology® 2018;91:983. doi:10.1212/WNL.0000000000006536
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Author response: The state of clinical research in neurology
Deborah A. Hall (Chicago)
Neurology® 2018;91:984. doi:10.1212/WNL.0000000000006542
Dr. Meador makes excellent points regarding our article addressing the state of clinical research in
neurology.1 The results of the survey showed that some areas of clinical research had clearly
worsened over the last 10 years, such as time spent on research or number of early career applicants
to the NIH. These results are consistent with a recent report by Dr. Meador2 addressing the
decline of clinical research in academic medical centers. However, survey respondents reported
improvement in other areas, including adequate support by institutional grants and the availability
of training opportunities.1 I agree that it will be important to monitor and address the drop in the
pipeline of neurologists and neuroscientists focused on neuroscience research. I also agree that
additional work is needed to distinguish changes within subgroups of researchers (such as between
pharmaceutical-sponsored and investigator-initiated research), to clearly distinguish and to eval-
uate changes in funding mechanisms other than K or R awards over time, and to investigate
individual pressures that decrease available time for research, such as the electronic medical record.
Continued vigilance in these areas is critical to ensuring a robust network of clinical researchers in
neuroscience that can bring the advances we need for our neurologic patients.
1. Hall DA, Ramos A, Gelfand JM, et al. The state of clinical research in neurology. Neurology 2018;90:e1347–e1354.
2. Meador KJ. Decline of clinical research in academic medical centers. Neurology 2015;85:1171–1176.
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Reader response: Progressive neurodegeneration following spinal
cord injury: Implications for clinical trials
James Domingue (Lafayette, LA)
Neurology® 2018;91:984–985. doi:10.1212/WNL.0000000000006541
In 37 years of general neurology practice, I have seen about 10 patients who had undergone cervical
decompression for spondolytic myelopathy. Neurologic deﬁcits (pain, weakness, spasticity) began
Editors’ note: Progressive neurodegeneration following spinal cord
injury: Implications for clinical trials
In an eﬀort to determine radiographic predictors of clinical outcome following traumatic
spinal cord injury (SCI), Ziegler et al. compared early and late brain/spine MRI ﬁndings
between patients with SCI and healthy controls. While early signs of atrophy throughout
whitematter tracts herald poorer functional recovery in patients with acute SCI in this case-
control study, Dr. Domingue reﬂects on the recovery—and eventual regression—he has
seen among patients with spondylotic myelopathy. As the investigators from the case-
control study acknowledge, the pathophysiology that underlies traumatic and nontraumatic
SCImay result in variable patterns of disease progression. The authors emphasize that their
observations on the MRI changes following spinal cord injury may provide outcome
measures to study in clinical trials.
James E. Siegler III, MD, and Steven Galetta, MD
Neurology® 2018;91:984. doi:10.1212/WNL.0000000000006538
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to progress after a period of stability; in some, improvement lasted years. At times, this deterioration
was 5 or more years postdecompression. The imaging and other studies provided no explanations.
The article by Ziegler et al.1 on progressive neurodegeneration following spinal cord injury is the
ﬁrst I have found that may relate to this observation. Would the authors comment on the possible
relationship of their ﬁndings to my observations?
1. Ziegler G, Grabher P, Thompson A, et al. Progressive neurodegeneration following spinal cord injury: implications for clinical trials.
Neurology 2018;90:e1257–e1266.
Copyright © 2018 American Academy of Neurology
Author response: Progressive neurodegeneration following spinal
cord injury: Implications for clinical trials
Patrick Freund (Zurich, Switzerland), Alan Thompson (London, UK), Armin Curt (Zurich, Switzerland),
Markus Hupp (Zurich, Switzerland), Nikolaus Weiskopf (Leipzig, Germany), Patrick Grabher (Zurich,
Switzerland), Daniel Altmann (London, UK), Karl Friston (London, UK), John Ashburner (London, UK),
and Gabriel Ziegler (Magdeburg, Germany)
Neurology® 2018;91:985. doi:10.1212/WNL.0000000000006540
We agree with Dr. Domingue’s observation that the trajectory of recovery after spinal cord
injury (SCI) is complex and diﬃcult to predict. We should clarify that in the present study, we
investigated the eﬀects of traumatic SCI on neurodegeneration across the neuroaxis.1 However,
we and others have shown that in cervical spondolytic myelopathy (i.e., nontraumatic SCI)
remote tissue speciﬁc cord pathology is also evident.2,3 Surprisingly, the extent of neuro-
degeneration is similar to traumatic SCI, although these patients with nontraumatic SCI had
only mild clinical symptoms.2 This suggests that, in a slow progressive disease (e.g., cervical
spondolytic myelopathy), the CNS can compensate for neurodegenerative processes for much
longer; however, with time, the competition between processes of reorganization and neuro-
degeneration is lost in favor of the latter. Nevertheless, the clinical viability of MRI-based
structural measures for monitoring and predicting recovery after nontraumatic and traumatic SCI
is feasible and will provide a tool to improve our understanding of the disease mechanism, which
aﬀects not only the spinal cord but also the brain after SCI.3–5 These new insights will enable us to
better predict individual recovery trajectories and identify patients who could proﬁt from further
interventions to delay, or even prevent, further clinical deterioration.
1. Ziegler G, Grabher P, Thompson A, et al. Progressive neurodegeneration following spinal cord injury: implications for clinical trials.
Neurology 2018;90:e1257–e1266.
2. Grabher P, Mohammadi S, Trachsler A, et al. Voxel-based analysis of grey and white matter degeneration in cervical spondylotic
myelopathy. Sci Rep 2016;6:24636.
3. Martin AR, De Leener B, Cohen-Adad J, et al. Monitoring for myelopathic progression with multiparametric quantitative MRI. PLoS
One 2018;13:e0195733.
4. Freund P,Weiskopf N, Ashburner J, et al. MRI investigation of the sensorimotor cortex and the corticospinal tract after acute spinal cord
injury: a prospective longitudinal study. Lancet Neurol 2013;12:873–881.
5. Freund P, Friston K, Thompson AJ, et al. Embodied neurology: an integrative framework for neurological disorders. Brain 2016;139:
1855–1861.
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